NL-OMON32293
Completed
Phase 4
International Study for the Prediction of Optimized Treatment - in Depression - iSPOT-D
Brain Resource Company0 sites112 target enrollmentTBD
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- depression
- Sponsor
- Brain Resource Company
- Enrollment
- 112
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
Trial is onging in other countries
Investigators
Eligibility Criteria
Inclusion Criteria
- •meet DSM\-IV criteria for primary diagnosis of MDD (patients), HAMD score\>16 (patients), age between 18\-65, Dutch fluency (patients and healty controls) signed a written informed consent (patients and health controls)
Exclusion Criteria
- •1\) presence of bipolar disorder, psychosis or primary eating disorders (patients) or current or previous diagnosis of MDD or other Axis 1 disorder (healthy controls) 2\) pregnancy and women of child bearing potential who are not taking a medically accepted form of contraception and are at risk of becoming pregnant during the study, 3\) breastfeeding, 4\) presence of contra\-indication of usage of Escitalopram, Sertraline or Venlafaxine XR (patients) 5\) usage of any antidepressant or CNS drug which can not be washed out prior to participation 6\) use of any medication which is known to be contraindicated with Escitalopram, Sertraline, or Venlafaxine XR 7\)evidence of either hyper or hypo\-thyroidism within previous 3 months, 8\) known medical condition, disease or neurological disorder which might, in the opinion of the investigator, interfere with the assessments to be made in the study or put subjects at increased risk when exposed to optimal doses of the drug treatment, 9\) personal history of physical brain injury or blow to the head that resulted in loss of consciousness of greater than five minutes, 10\) recent/current substance dependence in accordance with current ABS criteria in the past 6 months, 11\) participation in an investigational study within four months of the baseline visit in which subjects have received an experimental drug/device that could affect the primary end points of this study, 12\)subjects who, in the opininon of the investigator, have a severe impediment to vision, hearing and/or hand movement, which is likely to interfere wiht their ability to complete the testing batteries, 13\) subjects who, in the opininon of the investigator, are unable and/or unlikely to comprehend and follow the study procedures and instructions.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 4
International Study for the Prediction of Optimized Treatment - in ADHDADHDAttention Deficit/Hyperactivity Disorder10009841NL-OMON33496Brain Resource Company194
Completed
Phase 2
Prospective evaluation of the predictive value of a circulating tumor cell (CTC) sensitivity profile to Cisplatin chemotherapy in metastatic breast cancer patientsMetastatic breast cancermetastatic mammary cancer10006291NL-OMON44123Erasmus MC, Universitair Medisch Centrum Rotterdam67
Completed
Not Applicable
A prospective, multi-centre study investigating the incidence and prognosis of relapses, pseudo-relapses and other causes of (sub)acute neurological symptoms in patients with relapsing-remitting multiple sclerosis.NL-OMON55562Sint Elisabeth Ziekenhuis125
Completed
Phase 4
A Prospective, Randomized, Multi-center Study to Assess the SaFety of the Orsiro Mission Stent compared to the ResoLute Onyx Stent in Subjects at High Risk for Bleeding in combination With 1-month Dual Antiplatelet Therapy (DAPT).NL-OMON52323BIOTRONIK AG1
Completed
Not Applicable
Clinical Study to Evaluate the Safety and Performance of MANTA Vascular Closure DeviceAandoeningen aan de hartklepCardiac diseaseVascular intervention1001928010003184NL-OMON42594Essential Medical Inc.35